Base de dados : MEDLINE
Pesquisa : D20.777.608 [Categoria DeCS]
Referências encontradas : 395 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 40 ir para página                         

  1 / 395 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28112981
[Au] Autor:Kitanohara M; Yamamoto T; Masunaga S; Ohishi M; Komatsu Y; Nagase M
[Ad] Endereço:a Kitanohara Women's Clinic , Sendai-shi , Miyagi , Japan.
[Ti] Título:Effect of porcine placental extract on the mild menopausal symptoms of climacteric women.
[So] Source:Climacteric;20(2):144-150, 2017 Apr.
[Is] ISSN:1473-0804
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study assessed the effects of oral porcine placental extract (PPE) on the mild menopausal symptoms of climacteric women. METHODS: In this 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 50 climacteric Japanese women were randomized 1 : 1 to oral PPE (300 mg/day) or placebo. Menopausal symptoms were evaluated by using the Simplified Menopausal Index (SMI), as were serum estradiol (E2) and follicle stimulating hormone (FSH) levels. Blood biochemical and cellular and urinary tests were done to evaluate safety aspects of repeated oral administration of PPE. RESULTS: The total SMI score of the PPE group was significantly more improved after 12 weeks than that of the placebo group (p = 0.031). This score and three subscores (vasomotor, psychological, and somatic symptoms) were significantly improved at 8 and/or 12 weeks compared with the initial values in the PPE group (p < 0.05). E2 and FSH levels were not improved in either group. No adverse events were observed. CONCLUSIONS: Oral PPE at 300 mg/day improved the mild menopausal symptoms of climacteric women. Since oral PPE did not improve serum E2 and FSH levels, PPE is thought not to ameliorate hormonal balance itself but to improve subjective feelings of climacteric women.
[Mh] Termos MeSH primário: Menopausa/efeitos dos fármacos
Extratos Placentários/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Depressão/tratamento farmacológico
Método Duplo-Cego
Estradiol/sangue
Feminino
Hormônio Foliculoestimulante/sangue
Fogachos/tratamento farmacológico
Seres Humanos
Humor Irritável/efeitos dos fármacos
Japão
Menopausa/sangue
Meia-Idade
Inquéritos e Questionários
Suínos
Avaliação de Sintomas/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placental Extracts); 4TI98Z838E (Estradiol); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170322
[Lr] Data última revisão:
170322
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170124
[St] Status:MEDLINE
[do] DOI:10.1080/13697137.2017.1279140


  2 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26911970
[Au] Autor:Park SB; Kim KN; Sung E; Lee SY; Shin HC
[Ad] Endereço:Department of Family Practice and Community Health, Ajou University School of Medicine.
[Ti] Título:Human Placental Extract as a Subcutaneous Injection Is Effective in Chronic Fatigue Syndrome: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.
[So] Source:Biol Pharm Bull;39(5):674-9, 2016 May 01.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Chronic fatigue (CF) is a common reason for consulting a physician due to affecting quality of life, but only a few effective treatments are available. The aim of this study was to examine the effectiveness of subcutaneous injection of the human placental extract (HPE) on medically indescribable cases of CF and safety in a randomized, double-blind, placebo-controlled clinical trial. A total of 78 subjects with CF were randomly assigned to either a HPE group or a placebo group. Subjects in the HPE group were treated with HPE three times a week subcutaneously for 6 weeks, whereas those in the placebo group with normal saline. Then, the fatigue severity scale (FSS), visual analog scale (VAS) and multidimensional fatigue inventory (MFI) were measured in both CF group and chronic fatigue syndrome (CFS) and idiopathic chronic fatigue (ICF) subgroup. The FSS, VAS and MFI score at baseline were not different between the HPE and placebo group in total subjects with CF. In CFS group, the FSS (p=0.0242), VAS (p=0.0009) and MFI (p=0.0159) scores measured at the end of the study period decreased more in the HPE group than in the placebo group when compared with those at the baseline. There were no significant differences between the HPE group and placebo group in the mean change from baseline in FSS, VAS, and MFI in subjects with ICF during the study period. The subcutaneous injection of HPE was effective in the improvement of CFS.
[Mh] Termos MeSH primário: Síndrome de Fadiga Crônica/tratamento farmacológico
Extratos Placentários/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Feminino
Seres Humanos
Injeções Subcutâneas
Masculino
Meia-Idade
Extratos Placentários/efeitos adversos
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placental Extracts)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170201
[Lr] Data última revisão:
170201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160226
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b15-00623


  3 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26807656
[Au] Autor:Chang SW; Kim JY; Kim MJ; Kim GH; Yi JK; Lee DW; Kum KY; Kim EC
[Ad] Endereço:a Department of Conservative Dentistry ;
[Ti] Título:Combined effects of mineral trioxide aggregate and human placental extract on rat pulp tissue and growth, differentiation and angiogenesis in human dental pulp cells.
[So] Source:Acta Odontol Scand;74(4):298-306, 2016.
[Is] ISSN:1502-3850
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to evaluate the combined effects of mineral trioxide aggregate (MTA) and human placental extract (HPE) on cell growth, differentiation and in vitro angiogenesis of human dental pulp cells (HDPCs) and to identify underlying signal transduction mechanisms. In vivo dental pulp responses in rats for a pulp-capping agent were examined. MATERIALS AND METHODS: MTS assay. ALP activity test, alizarin red S staining and RT-PCR for marker genes were carried out to evaluate cell growth and differentiation. HUVEC migration, mRNA expression and capillary tube formation were measured to evaluate angiogenesis. Signal transduction was analysed using Western blotting and confocal microscopy. The pulps of rat maxillary first molars were exposed and capped with either MTA or MTA plus HPE. Histologic observation and scoring were performed. RESULTS: Compared to treatment of HDPCs with either HPE or MTA alone, the combination of HPE and MTA increased cell growth, ALP activity, mineralized nodules and expression of marker mRNAs. Combination HPE and MTA increased migration, capillary tube formation and angiogenic gene expression compared with MTA alone. Activation of Akt, mammalian target of rapamycin (mTOR), p38, JNK and ERK MAPK, Akt, and NF-κB were significantly increased by combining HPE and MTA compared with MTA alone. Pulp capping with MTA plus HPE in rats showed superior dentin bridge formation, odontoblastic layers and dentinal tubules and lower inflammatory cell response, compared to the MTA alone group. CONCLUSIONS: This study demonstrates for the first time that the use of MTA with HPE promotes cell growth, differentiation and angiogenesis in HDPCs, which were associated with mTOR, MAPK and NF-κB pathways. Direct pulp capping with HPE plus MTA showed superior results when compared with MTA alone. Thus, the combination of MTA and HPE may be useful for regenerative endodontics.
[Mh] Termos MeSH primário: Compostos de Alumínio/farmacologia
Compostos de Cálcio/farmacologia
Polpa Dentária/efeitos dos fármacos
Óxidos/farmacologia
Extratos Placentários/farmacologia
Silicatos/farmacologia
[Mh] Termos MeSH secundário: Fosfatase Alcalina/efeitos dos fármacos
Compostos de Alumínio/uso terapêutico
Animais
Calcificação Fisiológica/efeitos dos fármacos
Compostos de Cálcio/uso terapêutico
Capilares/efeitos dos fármacos
Diferenciação Celular/efeitos dos fármacos
Linhagem Celular
Movimento Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Polpa Dentária/irrigação sanguínea
Polpa Dentária/citologia
Dentina Secundária/efeitos dos fármacos
Combinação de Medicamentos
Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos
Seres Humanos
MAP Quinase Quinase 4/efeitos dos fármacos
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Masculino
Proteínas Quinases Ativadas por Mitógeno/efeitos dos fármacos
NF-kappa B/efeitos dos fármacos
Neovascularização Fisiológica/efeitos dos fármacos
Odontoblastos/citologia
Odontoblastos/efeitos dos fármacos
Óxidos/uso terapêutico
Extratos Placentários/uso terapêutico
Proteínas Proto-Oncogênicas c-akt/efeitos dos fármacos
Agentes de Capeamento da Polpa Dentária e Pulpectomia/uso terapêutico
Ratos
Ratos Sprague-Dawley
Transdução de Sinais/efeitos dos fármacos
Silicatos/uso terapêutico
Serina-Treonina Quinases TOR/efeitos dos fármacos
Proteínas Quinases p38 Ativadas por Mitógeno/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aluminum Compounds); 0 (Calcium Compounds); 0 (Drug Combinations); 0 (NF-kappa B); 0 (Oxides); 0 (Placental Extracts); 0 (Pulp Capping and Pulpectomy Agents); 0 (Silicates); 0 (mineral trioxide aggregate); EC 2.7.1.1 (TOR Serine-Threonine Kinases); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 2.7.11.24 (Mitogen-Activated Protein Kinases); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases); EC 2.7.12.2 (MAP Kinase Kinase 4); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:160126
[St] Status:MEDLINE
[do] DOI:10.3109/00016357.2015.1120882


  4 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26213164
[Au] Autor:Kim YC; Ahn JH; Kim MS
[Ad] Endereço:Clinical Assistant Professor, Department of Orthopaedic Surgery, St. Vincent's Hospital, Suwon, Korea.
[Ti] Título:Infectious Achilles Tendinitis After Local Injection of Human Placental Extracts: A Case Report.
[So] Source:J Foot Ankle Surg;54(6):1193-6, 2015 Nov-Dec.
[Is] ISSN:1542-2224
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Local injections of corticosteroids or human placental extracts are sometimes used for the treatment of resistant tendinitis or fasciitis. We report a case of infectious Achilles tendinitis complicated by calcaneal osteomyelitis after injection of human placental extracts for the Achilles tendinitis. She was treated with excision of the infected bone and tendon, followed by V-Y lengthening of the proximal portion of the Achilles tendon in a single stage. At 2 years postoperative, she remained symptom free without any signs of recurrence, and the follow-up magnetic resonance imaging scan demonstrated a well-maintained Achilles tendon with normal signal intensity.
[Mh] Termos MeSH primário: Abscesso/cirurgia
Tendão do Calcâneo/cirurgia
Calcâneo/cirurgia
Osteomielite/cirurgia
Extratos Placentários/efeitos adversos
Tendinopatia/terapia
[Mh] Termos MeSH secundário: Abscesso/etiologia
Adulto
Doença Crônica
Feminino
Seres Humanos
Injeções/efeitos adversos
Osteomielite/etiologia
Extratos Placentários/administração & dosagem
Âncoras de Sutura
Tendinopatia/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Placental Extracts)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151030
[Lr] Data última revisão:
151030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150728
[St] Status:MEDLINE


  5 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26047835
[Au] Autor:Han NR; Park CL; Kim NR; Kim HY; Yoou MS; Nam SY; Moon PD; Jeong HJ; Kim HM
[Ad] Endereço:Department of PharmacologyCollege of Korean Medicine, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 130-701, Republic of KoreaDepartment of Food TechnologyInflammatory Disease Research Center, Hoseo University, 20, Hoseo-ro 79beon-gil, Baebang-eup, Asan, Chungcheongnam-do 336-795, R
[Ti] Título:Protective effect of porcine placenta in a menopausal ovariectomized mouse.
[So] Source:Reproduction;150(3):173-81, 2015 Sep.
[Is] ISSN:1741-7899
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Menopause is a significant physiological phase that occurs as women's ovaries stop producing ovum and the production of estrogen declines. Human placenta and some amino acids are known to improve menopausal symptoms. In this study, we investigated that porcine placenta extract (PPE) and arginine (Arg), a main amino acid of PPE, would have estrogenic activities in ovariectomized (OVX) mice as a menopause mouse model, human breast cancer cell line (MCF-7) cells, and human osteoblast cell line (MG-63) cells. PPE or Arg significantly inhibited the body weight and increased the vagina weight compared to the OVX mice. PPE or Arg ameliorated the vaginal atrophy in the OVX mice. The levels of 17ß-estradiol and the activities of alkaline phosphatase (ALP) were significantly increased by PPE or Arg in the serum of OVX mice. Trabecular bone parameters such as bone mineral density and porosity were also improved by PPE or Arg in the OVX mice. In the MCF-7 and MG-63 cells, PPE or Arg significantly increased the cell proliferation, estrogen receptor ß mRNA expression, and estrogen-response elements luciferase activity. Finally, PPE or Arg increased the activations of ALP and extracellular signal-regulated kinase 1/2 in the MG-63 cells. These results indicate that PPE or Arg would have estrogenic and osteoblastic activity. Therefore, PPE or Arg may be useful as new pharmacological tools for treating menopausal symptoms including osteoporosis. Free Korean abstract: A Korean translation of this abstract is freely available at http://www.reproduction-online.org/content/150/3/173/suppl/DC1.
[Mh] Termos MeSH primário: Arginina/farmacologia
Menopausa/efeitos dos fármacos
Ovariectomia
Extratos Placentários/farmacologia
[Mh] Termos MeSH secundário: Fosfatase Alcalina/sangue
Animais
Atrofia
Biomarcadores/sangue
Densidade Óssea/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Estradiol/sangue
Receptor beta de Estrogênio/efeitos dos fármacos
Receptor beta de Estrogênio/genética
Receptor beta de Estrogênio/metabolismo
Feminino
Seres Humanos
Células MCF-7
Menopausa/sangue
Camundongos Endogâmicos BALB C
Modelos Animais
Tamanho do Órgão
Osteoblastos/efeitos dos fármacos
Osteoblastos/metabolismo
Gravidez
RNA Mensageiro/metabolismo
Suínos
Fatores de Tempo
Regulação para Cima
Vagina/efeitos dos fármacos
Vagina/metabolismo
Vagina/patologia
Ganho de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (ESR2 protein, human); 0 (Estrogen Receptor beta); 0 (Placental Extracts); 0 (RNA, Messenger); 4TI98Z838E (Estradiol); 94ZLA3W45F (Arginine); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150805
[Lr] Data última revisão:
150805
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150607
[St] Status:MEDLINE
[do] DOI:10.1530/REP-15-0157


  6 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25891654
[Au] Autor:Thakur G; Thomas S; Bhargava D; Pandey A
[Ad] Endereço:Reader, Department of Oral and Maxillofacial Surgery, People's College of Dental Sciences and Research Center, Bhopal, India.
[Ti] Título:Does Topical Application of Placental Extract Gel on Postoperative Fibrotomy Wound Improve Mouth Opening and Wound Healing in Patients With Oral Submucous Fibrosis?
[So] Source:J Oral Maxillofac Surg;73(7):1439.e1-10, 2015 Jul.
[Is] ISSN:1531-5053
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Placental extract has been used as a therapeutic agent with application in various fields of medicine. Placental extract is well known for its effects on wound healing with anti-inflammatory, antiplatelet, and angiogenic effects and is also a biogenic modulator. The present study evaluated the effect of placental extract on wound healing, mouth opening, and postoperative patient discomfort in patients with oral submucous fibrosis treated with fibrotomy with buccal fat pad coverage and coronoidectomy. MATERIALS AND METHODS: Ten subjects with oral submucous fibrosis who presented with mouth opening less than 20 mm were enrolled in the present prospective randomized controlled trial to assess the effects of placental extract on the fibrotomy wound covered with a pedicled buccal pad fat (5 patients allocated to the study group, group S and 5 to the control group, group C). The following criteria were used to analyze the postoperative effect of placental extract on fibrotomy wounds compared with that of the controls: subjective assessment of the wound, postoperative discomfort, and postoperative mouth opening assessed at 1, 2, and 4 weeks postoperatively. RESULTS: The average difference in the preoperative and fourth week postoperative mouth opening for group C was 13.8 ± 2.68 mm and was 21.20 ± 2.77 mm in group S. The median calculated for group C was a 15.0-mm increase in mouth opening and was 20.0 mm in group S. CONCLUSION: The results obtained with topical application of placental extract on fibrotomy wound healing and postoperative mouth opening were superior to those of the control group in whom placental extract was not used.
[Mh] Termos MeSH primário: Mucosa Bucal/efeitos dos fármacos
Fibrose Oral Submucosa/cirurgia
Dor Pós-Operatória/prevenção & controle
Extratos Placentários/uso terapêutico
Trismo/cirurgia
[Mh] Termos MeSH secundário: Tecido Adiposo/transplante
Administração através da Mucosa
Adulto
Autoenxertos/transplante
Tecido Conjuntivo/efeitos dos fármacos
Tecido Conjuntivo/cirurgia
Epitélio/patologia
Seguimentos
Géis
Tecido de Granulação/patologia
Seres Humanos
Masculino
Mandíbula/cirurgia
Mucosa Bucal/cirurgia
Medição da Dor/métodos
Modalidades de Fisioterapia
Extratos Placentários/administração & dosagem
Estudos Prospectivos
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Gels); 0 (Placental Extracts)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150619
[Lr] Data última revisão:
150619
[Sb] Subgrupo de revista:AIM; D; IM
[Da] Data de entrada para processamento:150421
[St] Status:MEDLINE


  7 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25787854
[Au] Autor:Kwon TR; Oh CT; Park HM; Han HJ; Ji HJ; Kim BJ
[Ad] Endereço:Department of Medicine, Graduate School, Chung-Ang University, Seoul, Korea.
[Ti] Título:Potential synergistic effects of human placental extract and minoxidil on hair growth-promoting activity in C57BL/6J mice.
[So] Source:Clin Exp Dermatol;40(6):672-81, 2015 Aug.
[Is] ISSN:1365-2230
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Human placenta extract (HPE) has been used to alleviate tiredness and promote wound healing, and for its antiageing functions; however, it has not yet been studied for its effects on hair growth. In the present study, we evaluated the in vitro effect of HPE on hair growth by observing its actions on human dermal papilla cells (DPCs). AIM: To define how HPE promotes induction of anagen hair growth during the telogen phase, and to understand the synergistic molecular mechanisms of HPE and minoxidil (MXD) actions on hair growth. METHODS: We examined the effects of HPE and MXD on C57BL6/J mice using haematoxylin and eosin staining, quantitative histomorphometry, hair growth scoring, immunohistochemistry and immunofluorescence on the dorsal skins of C57BL/6J mice. RESULTS: We found that HPE synergistically augmented the effects of MXD, a promoter of hair growth. In particular, histomorphometric analysis data indicated that subcutaneous injection of HPE induced an earlier anagen phase and prolonged the anagen phase. It also stimulated increases in both the number and size of hair follicles in groups treated with HPE alone and HPE + MXD. CONCLUSIONS: From our data, we conclude that HPE increases ß-catenin and Wnt3a expression levels. Overall, our findings suggest that HPE in combination with MXD has hair growth-promoting activity and is a potential novel therapeutic treatment for alopecia or baldness in humans.
[Mh] Termos MeSH primário: Cabelo/efeitos dos fármacos
Minoxidil/farmacologia
Extratos Placentários/farmacologia
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: Alopecia/tratamento farmacológico
Análise de Variância
Animais
Proliferação Celular/efeitos dos fármacos
Derme/citologia
Sinergismo Farmacológico
Feminino
Cabelo/crescimento & desenvolvimento
Folículo Piloso/efeitos dos fármacos
Seres Humanos
Camundongos
Camundongos Endogâmicos C57BL
Modelos Animais
beta Catenina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Placental Extracts); 0 (Vasodilator Agents); 0 (beta Catenin); 5965120SH1 (Minoxidil)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150718
[Lr] Data última revisão:
150718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150320
[St] Status:MEDLINE
[do] DOI:10.1111/ced.12601


  8 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25435062
[Au] Autor:Yamasaki M; Hasegawa S; Takahashi H; Kobayashi Y; Sakai C; Ashizawa Y; Asai Y; Kanzaki M; Fukui T
[Ad] Endereço:a Department of Health Chemistry , Hoshi University , 2-4-41, Ebara, Shinagawa-Ku, Tokyo 142-8501 , Japan.
[Ti] Título:Placental extracts induce the expression of antioxidant enzyme genes and suppress melanogenesis in B16 melanoma cells.
[So] Source:Nat Prod Res;29(22):2103-6, 2015.
[Is] ISSN:1478-6427
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:One of the activities of placental extracts (PEs) is skin-whitening effect, but the physiological and genetic mechanism for this effect has not yet been clarified. Here, we focus on PE as a regulator of antioxidant enzyme genes. Porcine PE was prepared, and its activity was investigated in B16 melanoma cells. PE treatment decreased the melanin content of UV-irradiated B16 cells in a dose-dependent manner. PE directly reduced the enzyme activity of tyrosinase in a cell-free assay. In addition, PE treatment increased the gene expression of cytosolic superoxide dismutase (SOD-1), extracellular SOD (SOD-3) and catalase but did not affect the expression of tyrosinase. Moreover, PE protected the B16 cells from H2O2-induced cell death. Taken together, our data suggest that PEs could play a role not only as a suppressor of melanin synthesis but also as a regulator of antioxidant genes and might protect the skin against oxidative stress.
[Mh] Termos MeSH primário: Antioxidantes/metabolismo
Melanoma Experimental/metabolismo
Extratos Placentários/farmacologia
[Mh] Termos MeSH secundário: Animais
Catalase/metabolismo
Linhagem Celular Tumoral
Melaninas/metabolismo
Monofenol Mono-Oxigenase/antagonistas & inibidores
Monofenol Mono-Oxigenase/metabolismo
Superóxido Dismutase/metabolismo
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Melanins); 0 (Placental Extracts); EC 1.11.1.6 (Catalase); EC 1.14.18.1 (Monophenol Monooxygenase); EC 1.15.1.1 (Superoxide Dismutase)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150923
[Lr] Data última revisão:
150923
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141202
[St] Status:MEDLINE
[do] DOI:10.1080/14786419.2014.986660


  9 / 395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25266486
[Au] Autor:Mitsui Y; Bagchi M; Marone PA; Moriyama H; Bagchi D
[Ad] Endereço:Horus Co., Ltd. , Tokyo , Japan .
[Ti] Título:Safety and toxicological evaluation of a novel, fermented, peptide-enriched, hydrolyzed swine placenta extract powder.
[So] Source:Toxicol Mech Methods;25(1):13-20, 2015 Jan.
[Is] ISSN:1537-6524
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Placenta is an important organ that connects the developing fetus to allow nutrient uptake, antibody provisions and gas exchange via the blood supply of the mother. We developed a novel, standardized, stable, water-soluble, peptide-enriched hydrolyzed, Horus fermented placenta powder (HFPEP) from healthy, pathogen-free, swine placenta. Earlier studies demonstrated that HFPEP significantly improves physical fatigue, hepatic functions and repair of muscle fibers. We examined the broad safety of HFPEP in various toxicology models in Good Laboratory Practices-approved laboratories. The acute oral toxicity study was conducted in female Sprague-Dawley rats, and the acute oral LD50 was found to be greater than 5000 mg/kg body weight. Ames' bacterial reverse mutation assay was conducted to determine the ability of HFPEP to induce reverse mutation at selected histidine loci in five tester strains of Salmonella typhimurium viz. TA1535, TA1537, TA98, TA100 and TA102 in the presence and absence of a metabolic activation system (S9) at the doses of 50, 15, 4.5, 1.35 and 0.41 mg/ml. No mutagenic potential was observed. Mutagenic potential was also evaluated using in vivo micronucleus test, and no mutagenic potential of HFPEP was observed. Repeated dose 28-d oral toxicity study was performed in male and female rats with 14-d recovery period at the dose levels of 250, 500 or 1000 mg/kg. No abnormal clinical signs or toxicity were detected. No observed adverse effect level of HFPEP was found to be greater than 1000 mg/kg body weight. These studies affirm that HFPEP has broad spectrum safety for human consumption.
[Mh] Termos MeSH primário: Fermentação
Peptídeos/toxicidade
Extratos Placentários/toxicidade
[Mh] Termos MeSH secundário: Administração Oral
Animais
Feminino
Dose Letal Mediana
Masculino
Micronúcleos com Defeito Cromossômico/induzido quimicamente
Testes para Micronúcleos
Mutação
Nível de Efeito Adverso não Observado
Peptídeos/administração & dosagem
Extratos Placentários/administração & dosagem
Pós
Ratos Sprague-Dawley
Medição de Risco
Salmonella typhimurium/efeitos dos fármacos
Salmonella typhimurium/genética
Suínos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Peptides); 0 (Placental Extracts); 0 (Powders)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141219
[Lr] Data última revisão:
141219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141001
[St] Status:MEDLINE
[do] DOI:10.3109/15376516.2014.971139


  10 / 395 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:25799800
[Au] Autor:Shrestha S; Jha AK; Thapa DP; Bhattarai CK; Ghimire A
[Ti] Título:An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area.
[So] Source:Nepal Med Coll J;16(1):1-4, 2014 Sep.
[Cp] País de publicação:Nepal
[La] Idioma:eng
[Ab] Resumo:Vitiligo is a common skin disorder affecting about 1 to 2% of the world population. The prevalence in Nepal is 2-3%. This disease is associated with profound psychological distress. Though many treatment options are available none of these are universally effective. The main objective of the study is to compare the efficacy and rate of repigmentation with use of topical steroid and topical placental extract versus topical steroid and topical tacrolimus 0.1% in treating patients with localized vitiligo. One hundred patients visiting the dermatology outpatient department of Nepal Medical College and Teaching Hospital with the diagnosis of vitiligo involving less than 10% of body surface area were taken. 50 of these patients (Category A) were randomly selected and treated with topical steroid (Mometasone furoate 0.1% cream) and Topical placental extract gel. Other 50 patients (Category B) were given the same topical steroid with Topical Tacrolimus 0.1% cream. The patients were examined every month and final outcome was seen at the end of 3 months. Of the total 100 patients 51% were male and 49% were female. Seventeen percent of patients had lesions over face and neck, 49% had lesions over the extremities and 34% had lesions over trunk. At the end of 3 months the rate of repigmentation was better in patients of Category B than Category A and the result was statistically significant. Topical Tacrolimus 0.1% ointment could be better option for the treatment of localized vitiligo when compared to topical placental extract but in combination with a steroid cream.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Imunossupressores/uso terapêutico
Extratos Placentários/uso terapêutico
Pregnadienodiois/uso terapêutico
Tacrolimo/uso terapêutico
Vitiligo/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Adolescente
Adulto
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Furoato de Mometasona
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Immunosuppressive Agents); 0 (Placental Extracts); 0 (Pregnadienediols); 04201GDN4R (Mometasone Furoate); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150325
[St] Status:MEDLINE



página 1 de 40 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde